To further investigate the predictive capacity of NSD3 for the clinical outcome of immunotherapy, we mined bulk RNA-Seq data and clinical information from one NSCLC immunotherapy cohort treated with anti-PD-1/PD-L1. Here, CD274 is linked to non-small cell lung carcinoma.